Production of recombinant scFv against p24 of human immunodeficiency virus type 1 by phage display technology

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 33, Issue 1, 2014, Pages 28-33

  Mohammadzadeh, Sara ^a   Rajabibazl, Masoumeh ^b   Fourozandeh, Mehdi ^a   Rasaee, Mohammad Javad ^a   Rahbarizadeh, Fatemeh ^a   Mohammadi, Mohammad ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODY SPECIFICITY; CELL SURFACE DISPLAY TECHNIQUES; DNA PRIMERS; HIV INFECTIONS; HIV-1; HUMANS; MICE; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; RETROVIRIDAE PROTEINS, ONCOGENIC; SINGLE-CHAIN ANTIBODIES;

EID: 84894564282     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2013.0059     Document Type: Article

References (31)

1. Adams GP, Horak EM, Weiner LM, and Marks JD: Bispecific single chain FV antibody molecules and methods of use thereof. EP Patent 2,425,850, 2012.
2. Gavilondo JV, and Larrick JW: Antibody engineering at the millennium. Biotechniques 2000;29:128-145.
3. Howard GC, and Bethell DR: Basic Methods in Antibody Production and Characterization. CRC Press, Boca Raton, FL, 2009.
4. Johnston CM, Wood AL, Bolland DJ, and Corcoran AE: Complete sequence assembly and characterization of the C57BL/6 mouse Ig heavy chain V region. J Immunol 2006;176:4221-4234.
5. Khudyakov YE, and Fields HA: Artificial DNA: Methods and Applications. CRC Press, Boca Raton, FL, 2010.
6. Ladner RC: Phage display and pharmacogenomics. Pharmacogenomics 2000;1:199-202.
7. Xu JL, and Davis MM: Diversity in the CDR3 region of VH is sufficient for most antibody specificities. Immunity 2000;13:37-45.
8. Pawlitzky I, Angeles CV, Siegel AM, Stanton ML, Riblet R, and Brodeur PH: Identification of a candidate regulatory element within the 5 flanking region of the mouse Igh locus defined by pro-B cell-specific hypersensitivity associated with binding of PU. 1, Pax5, and E2A. J Immunol 2006;176:6839-6851.
9. Petrenko VA, and Vodyanoy VJ: Phage display for detection of biological threat agents. J Microbiol Methods 2003; 53:253-262.
10. Ye J: The immunoglobulin IGHD gene locus in C57BL/6 mice. Immunogenetics 2004;56:399-404.
11. Iroegbu J, Birk M, Lazdina U, Sönnerborg A, and Sällberg M: Variability and immunogenicity of human immunodeficiency virus type 1 p24 gene quasispecies. Clin Diagn Lab Immunol 2000;7:377-383.
12. Sutthent R, Gaudart N, Chokpaibulkit K, Tanliang N, Kanoksinsombath C, and Chaisilwatana P: p24 antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. J Clin Microbiol 2003;41:1016-1022.
13. Schüpbach J: Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. International Arch Allergy Immunol 2003;132:196-209.
14. Holliger P, and Hudson PJ: Engineered antibody fragments and the rise of single domains Nat Biotechnol 2005;23: 1126-1136.
15. Sokolskaja E, Sayah DM, and Luban J: Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004;78:12800-12808.
16. Ravanshad M, Sabahi F, and Mahboudi F: Quantification analysis of dot blot assays for human immunodeficiency virus type 1 and 2 antibodies. Iran J Basic Med Sci 2007; 10:210-215.
17. Kramer K, Fiedler M, Skerra A, and Hock B: A generic strategy for subcloning antibody variable regions from the scFv phage display vector pCANTAB 5 E into pASK85 permits the economical production of Fab fragments and leads to improved recombinant immunoglobulin stability. Biosensors Bioelect 2002;17:305-313.
18. Alirezapour B, Rajabibazl M, Rasaee MJ, and Omidfar K: Production and characterization of recombinant scFv against digoxin by phage display technology. Monoclon Antib Immunodiagn Immunother 2013;32:172-179.
19. Hoogenboom HR: Overview of Antibody Phage-Display Technology and Its Applications, in Antibody Phage Display. Springer, New York, 2002. pp. 1-37.
20. Castagnoli L, Zuccconi A, Quondam M, Rossi M, Vaccaro P, Panni S, Paoluzi S, Santonico E, Dente L, and Cesareni G: Alternative bacteriophage display systems. Combin Chem High Throughput Screen 2001;4:121-133.
21. Lin H, and Cornish VW: Screening and selection methods for large-scale analysis of protein function. Ange Chem Intl Ed 2002;41:4402-4425.
22. Ebrahimizadeh W, Gargari SM, Rajabibazl M, Ardekani LS, Zare H, and Bakherad H: Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol 2013;97:4457-4466.
23. Barbas CF, Burton DR, Scott JK, and Silverman GJ: Phage Displays: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.
24. Baek H, Suk K-h, Kim Y-h, and Cha S: An improved helper phage system for efficient isolation of specific antibody molecules in phage display. Nucl Acid Res 2002; 30:e18-e18.
25. Levy R, Weiss R, Chen G, Iverson BL, and Georgiou G: Production of correctly folded fab antibody fragment in the cytoplasm of Escherichia coli trxb gor mutants via the coexpression of molecular chaperones. Prot Express Purific 2001;23:338-347.
26. Hoogenboom HR, and Chames P: Natural and designer binding sites made by phage display technology. Immunol Today 2000;21:371-378.
27. Kim SJ, Park Y, and Hong HJ: Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005;20:17-29.
28. Kretzschmar T, and von Rüden T: Antibody discovery: phage display. Current Opin Biotechnol 2002;13:598-602.
29. Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, and Picker LJ: HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011;3:79.
30. Goulder PJ, and Watkins DI: HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004;4: 630-640.
31. Kontermann RE: Intrabodies as therapeutic agents. Methods 2004;34:163-170.